Treatment related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) are well known complications after chemotherapy for various hematologic and non-hematologic malignancies. Alkylating agents and Topoisomerase inhibitors are most widely studied in this regard. There is growing concern about occurrence of t-MDS, t-MDS/AML and t-AML in patients of CLL treated with nucleoside analogues especially in combination with alkylating agents. Exact incidence and pathogenesis of nucleoside analogue related MDS/AML is not clear at this time. We hereby report a case of t-AML in a patient treated with Fludarabine, Cyclophosphamide and Rituximab (FCR) for CLL. The cytogenetic studies revealed a unique translocation t (10:16), that has been reported in very few cases of therapy related AML and pediatric AML.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269801PMC
http://dx.doi.org/10.4081/hr.2011.e23DOI Listing

Publication Analysis

Top Keywords

acute myeloid
8
myeloid leukemia
8
alkylating agents
8
therapy acute
4
leukemia t1016
4
t1016 rare
4
rare entity
4
entity treatment
4
treatment myelodysplastic
4
myelodysplastic syndrome
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!